Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

277 Views

226. Antimicrobial Novel Agents: Saturday, 12:15 - 1:30 p.m.

Poster Session: Antimicrobial Novel Agents

(2144) A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics (PK) of Oral Epetraborole Tablets in Adult Subjects with Varying Degrees of Renal Function

Saturday, October 14, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Gina Patel, MPharm, PhD (she/her/hers)

President and CEO
Patel Kwan Consultancy LLC
Middleton, Wisconsin, United States

GC

George C. Canas, MD

Kidney Specialists of Minnesota
Brooklyn Center, Minnesota, United States
KC

Kimberly Cruz, MD

Advanced Pharma CR, LLC
Miami, Florida, United States
TM

Thomas C. Marbury, MD

President
Orlando Clinical Research Center
Orlando, FL, United States
MG

Mark Gotfried, MD

University of Arizona, Phoenix
Phoenix, Arizona, United States
WC

Wallace (Boon Chun) Chan, BS

Patel Kwan Consultancy
Madison, Wisconsin, United States
KD

Kenneth Duchin, PhD

Patel Kwan Consultancy
Madison, Wisconsin, United States
GM

Gary Maier, PhD

Maier Metrics and Associates, LLC
Worcester, Massachusetts, United States
SC

Sanjay Chanda, PhD

AN2 Therapeutics, Inc.
Menlo Park, California, United States
LK

Linda Kammerer, BS

AN2 Therapeutics
Menlo Park, California, United States
JL

Jennifer Long, MSPH

AN2 Therapeutics, Inc.
Menlo Park, California, United States
SM

Stephanie Moore, BS

AN2 Therapeutics
Menlo Park, California, United States
KO

Kevin O'Shea, BS

AN2 Therapeutics
Menlo Park, California, United States
Afshin Shafiee, PhD (he/him/his)

Sr. Director, Toxicology
AN2 Therapeutics
Oakland, California, United States
AS

Alex Smith, MS

AN2 Therapeutics
Menlo Park, California, United States
Paul B. Eckburg, MD (he/him/his)

Chief Medical Officer
AN2 Therapeutics
Mountain View, CA, United States